



February 28, 2018

## **Flexion Therapeutics to Present at the 39th Annual Raymond James Institutional Investors Conference**

BURLINGTON, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at the Raymond James 39<sup>th</sup> Annual Institutional Investors Conference in Orlando, Florida. Dr. Clayman is scheduled to present at 8:05 a.m Eastern Time on Tuesday, March 6, 2018. Investors can access the live webcast and subsequent archived recording of the presentation by visiting the Flexion website at <http://ir.flexiontherapeutics.com>

### **About Flexion Therapeutics**

Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. Flexion was named one of *The Boston Business Journal's* 2017 Best Places to Work and one of the Top Places to Work in Massachusetts by *The Boston Globe*.

### **Corporate Contact:**

Scott Young  
Vice President, Corporate Communications and Investor Relations  
Flexion Therapeutics, Inc.  
T: 781-305-7194  
[syoung@flexiontherapeutics.com](mailto:syoung@flexiontherapeutics.com)